BR112022016197A2 - Polipeptídeos e seus usos - Google Patents

Polipeptídeos e seus usos

Info

Publication number
BR112022016197A2
BR112022016197A2 BR112022016197A BR112022016197A BR112022016197A2 BR 112022016197 A2 BR112022016197 A2 BR 112022016197A2 BR 112022016197 A BR112022016197 A BR 112022016197A BR 112022016197 A BR112022016197 A BR 112022016197A BR 112022016197 A2 BR112022016197 A2 BR 112022016197A2
Authority
BR
Brazil
Prior art keywords
polypeptides
nanoparticles
designing
disclosed
methods
Prior art date
Application number
BR112022016197A
Other languages
English (en)
Inventor
P King Neil
Walkey Carl
Yang Wang Jing
FIALA Brooke
Veesler David
C Walls Alexandra
NATTERMANN Una
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Publication of BR112022016197A2 publication Critical patent/BR112022016197A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/20—Protein or domain folding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/50—Mutagenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/00021—Viruses as such, e.g. new isolates, mutants or their genomic sequences

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)

Abstract

POLIPEPTÍDEOS E SEUS USOS. Polipeptídeos são divulgados aqui tendo capacidade de secreção significativamente melhorada de células eucarióticas, juntamente com proteínas de fusão, nanopartículas e usos das mesmas, e métodos para projetar tais polipeptídeos.
BR112022016197A 2020-02-14 2021-02-12 Polipeptídeos e seus usos BR112022016197A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062977036P 2020-02-14 2020-02-14
PCT/US2021/017856 WO2021163481A1 (en) 2020-02-14 2021-02-12 Polypeptides and their use

Publications (1)

Publication Number Publication Date
BR112022016197A2 true BR112022016197A2 (pt) 2022-10-25

Family

ID=77292738

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022016197A BR112022016197A2 (pt) 2020-02-14 2021-02-12 Polipeptídeos e seus usos

Country Status (10)

Country Link
US (1) US20230075095A1 (pt)
EP (1) EP4103586A4 (pt)
JP (1) JP2023513592A (pt)
KR (1) KR20220142471A (pt)
AU (1) AU2021220958A1 (pt)
BR (1) BR112022016197A2 (pt)
CL (1) CL2022002215A1 (pt)
CO (1) CO2022011395A2 (pt)
PE (1) PE20230486A1 (pt)
WO (1) WO2021163481A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023196871A2 (en) * 2022-04-07 2023-10-12 University Of Washington Secretion-optimized de novo designed protein nanoparticles for eukaryotic expression and genetic delivery

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4896013B2 (ja) * 2004-06-16 2012-03-14 ディーエスエム アイピー アセッツ ビー．ブイ． 改良された分泌によるポリペプチドの製造
US9630994B2 (en) * 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
WO2016138525A1 (en) * 2015-02-27 2016-09-01 University Of Washington Polypeptide assemblies and methods for the production thereof
JP6957039B2 (ja) * 2016-09-06 2021-11-02 学校法人慶應義塾 融合タンパク質、構造体、捕集剤、捕集する方法、ｄｎａ、及びベクター
US11866699B2 (en) * 2017-02-10 2024-01-09 University Of Washington Genome editing reagents and their use
RU2019130167A (ru) * 2017-04-04 2021-05-05 Юниверсити Оф Вашингтон Самосборные белковые наноструктуры, экспонирующие f-белки парамиксовируса и/или пневмовируса, и их применение
CN112088014A (zh) * 2018-02-28 2020-12-15 华盛顿大学 自组装纳米结构疫苗
FR3083804B1 (fr) * 2018-07-13 2022-08-12 Institut Nat Des Sciences Appliquees De Toulouse Micro-organismes et procede pour la production d'acide glycolique a partir de pentoses et d'hexoses

Also Published As

Publication number Publication date
EP4103586A1 (en) 2022-12-21
KR20220142471A (ko) 2022-10-21
PE20230486A1 (es) 2023-03-21
WO2021163481A1 (en) 2021-08-19
CO2022011395A2 (es) 2023-01-16
EP4103586A4 (en) 2024-05-15
US20230075095A1 (en) 2023-03-09
AU2021220958A1 (en) 2022-09-01
CL2022002215A1 (es) 2023-05-05
JP2023513592A (ja) 2023-03-31

Similar Documents

Publication Publication Date Title
BR112021022874A2 (pt) Proteínas de ligação epcam e métodos de uso
CL2022000300A1 (es) Muteínas de interleucina 21 y sus usos para tratar tumores sólidos (divisional de la solicitud no. 202000252)
CL2020002477A1 (es) Proteínas de fusión interleucina-2/receptor alfa de interleucina-2 y métodos de uso
MX2021015452A (es) Proteinas de fusion flt3l-fc y metodos de uso.
MX2020009371A (es) Composiciones y métodos para la reprogramación de tcr mediante el uso de proteínas de fusión.
MX2020003504A (es) Receptores de celulas t que reconocen p53 mutado.
EA202090931A2 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
DK1356052T3 (da) Produktion af hele antistoffer i prokaryotiske celler
BR112018070250A2 (pt) linhagem celular para proteína recombinante e/ou produção de vetores virais
TR201910802T4 (tr) T-regülatör hücrelerin genişletilmesine yönelik interlökin-2 muteinleri.
WO2009130618A3 (en) Flagellin polypeptide vaccines
IL275779A (en) Recombinant human sialidases, sialidase-related proteins and methods of using them
EA201791918A1 (ru) Модификация белков клеток-хозяев
BR112022008514A2 (pt) Terapia de células t com receptor de antígeno quimérico
BR112022016197A2 (pt) Polipeptídeos e seus usos
BR112022006842A2 (pt) Construtos de igf2 variante
BR112017017609A2 (pt) proteína de fusão fc, e, composição farmacêutica.
CR20210478A (es) Proteínas de fusión, bacterias recombinantes, y fragmentos de exosporio para el control de plagas y salud vegetal
CL2023001433A1 (es) Muteína de il-2; proteína de fusión; ácido nucleico; vector; célula hospedera; métodos; uso
MX2020013217A (es) Metodos para generar celulas madre hematopoyeticas.
BR112022003852A2 (pt) Métodos de preparação de células t para terapia de células t
BR112012015461A2 (pt) polipeptídeos de somatotropina boviina modificados e seus usos
EP3994275A4 (en) RECOMBINANT HUMAN SIALIDASES, SIALIDASE FUSION PROTEINS AND METHODS OF USE THEREOF
MX2022012062A (es) Receptores de linfocitos t.
BR112021019109A2 (pt) Célula rpe manipulada, composições, molécula isolada de dna de fita dupla, dispositivo implantável, cápsula de hidrogel, e, método para aplicar uma terapia com fvii